|
Market Closed -
NSE India S.E.
07:05:07 2026-10-16 EDT
|
5-day change | 1st Jan Change | ||
| 2,226.70 INR | -1.06% |
|
-2.89% | +9.41% |
| 09-11 | Glenmark Pharmaceuticals Limited Proposes Dividend for the Year Ended 31 March 2026 | CI |
| 09-07 | Acucort wins trademark protection for Zeqmelit in Ukraine | FW |
Company Valuation: Glenmark Pharmaceuticals Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 124,718 | 131,124 | 270,463 | 434,866 | 601,567 | 628,377 | - | - |
| Change | - | 5.14% | 106.27% | 60.79% | 38.33% | 4.46% | - | - |
| Enterprise Value (EV) 1 | 150,223 | 162,699 | 263,786 | 442,540 | 595,740 | 592,627 | 581,214 | 571,253 |
| Change | - | 8.3% | 62.13% | 67.76% | 34.62% | -0.52% | -1.93% | -1.71% |
| P/E | 13.2x | 44.1x | -18x | 41.5x | 44.2x | 27.2x | 22.5x | 20.1x |
| PBR | 1.37x | 1.38x | 3.45x | 4.91x | 5.72x | 5.01x | 4.14x | 3.55x |
| PEG | - | -0.6x | 0x | -0x | 1.5x | 0.4x | 1.1x | 1.7x |
| Capitalization / Revenue | 1.01x | 1.01x | 2.29x | 3.26x | 3.54x | 3.71x | 3.35x | 2.99x |
| EV / Revenue | 1.22x | 1.25x | 2.23x | 3.32x | 3.51x | 3.5x | 3.1x | 2.72x |
| EV / EBITDA | 6.47x | 7.14x | 22.1x | 18.8x | 13x | 16.3x | 13.3x | 11.8x |
| EV / EBIT | 8.19x | 9.76x | 43x | 23.7x | 14.9x | 19.3x | 15.7x | 14.3x |
| EV / FCF | 47.2x | 923x | -22.7x | -28.1x | 28.5x | 35.6x | 30.7x | 26.4x |
| FCF Yield | 2.12% | 0.11% | -4.41% | -3.56% | 3.5% | 2.81% | 3.26% | 3.78% |
| Dividend per Share 2 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 3.82 | 4.02 | 3.75 |
| Rate of return | 0.57% | 0.54% | 0.26% | 0.16% | 0.12% | 0.17% | 0.18% | 0.17% |
| EPS 2 | 33.4 | 10.53 | -53.22 | 37.11 | 48.24 | 81.95 | 99.11 | 110.6 |
| Distribution rate | 7.49% | 23.7% | -4.7% | 6.74% | 5.18% | 4.66% | 4.06% | 3.39% |
| Net sales 1 | 123,409 | 129,901 | 118,131 | 133,217 | 169,825 | 169,493 | 187,310 | 210,339 |
| EBITDA 1 | 23,203 | 22,784 | 11,953 | 23,514 | 45,724 | 36,398 | 43,540 | 48,545 |
| EBIT 1 | 18,336 | 16,671 | 6,134 | 18,654 | 39,989 | 30,630 | 36,990 | 39,859 |
| Net income 1 | 9,936 | 2,972 | -15,017 | 10,471 | 13,619 | 23,694 | 28,322 | 30,213 |
| Net Debt 1 | 25,505 | 31,575 | -6,677 | 7,674 | -5,827 | -35,750 | -47,162 | -57,124 |
| Reference price 2 | 442.00 | 464.70 | 958.45 | 1,541.05 | 2,131.70 | 2,226.70 | 2,226.70 | 2,226.70 |
| Nbr of stocks (in thousands) | 282,168 | 282,168 | 282,188 | 282,188 | 282,201 | 282,201 | - | - |
| Announcement Date | 5/27/22 | 5/19/23 | 5/24/24 | 5/23/25 | 5/29/26 | - | - | - |
1INR in Million2INR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 27.17x | 3.5x | 16.28x | 0.17% | 6.62B | |
| 35.96x | 12.96x | 27.14x | 0.55% | 1,120B | |
| 37.4x | 6.3x | 17.74x | 2.09% | 616B | |
| 36.43x | 8.36x | 17.24x | 2.43% | 504B | |
| 20.46x | 4.99x | 12.38x | 2.64% | 367B | |
| 106.52x | 5.95x | 25.12x | 2.33% | 360B | |
| 21.18x | 5.54x | 13.63x | 2.88% | 288B | |
| 21.7x | 4.38x | 12.55x | 2.01% | 258B | |
| 27.46x | 7.06x | 12.64x | 2.33% | 234B | |
| -45.63x | 6.99x | 27.07x | 2.11% | 194B | |
| Average | 28.87x | 6.60x | 18.18x | 1.96% | 394.75B | |
| Weighted average by Cap. | 34.71x | 8.19x | 20.03x | 1.83% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GLENMARK Stock
- Valuation Glenmark Pharmaceuticals Limited
Select your edition
All financial news and data tailored to specific country editions
